Aptevo Therapeutics (APVO) EBT (2016 - 2022)
Historic EBT for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to -$7.7 million.
- Aptevo Therapeutics' EBT fell 9019.8% to -$7.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$28.6 million, marking a year-over-year decrease of 3383.64%. This contributed to the annual value of -$18.6 million for FY2023, which is 3488.36% up from last year.
- Aptevo Therapeutics' EBT amounted to -$7.7 million in Q4 2022, which was down 9019.8% from -$7.8 million recorded in Q3 2022.
- Aptevo Therapeutics' 5-year EBT high stood at -$4.0 million for Q4 2021, and its period low was -$13.9 million during Q1 2018.
- Moreover, its 5-year median value for EBT was -$7.6 million (2022), whereas its average is -$8.7 million.
- Per our database at Business Quant, Aptevo Therapeutics' EBT soared by 4721.62% in 2020 and then crashed by 9019.8% in 2022.
- Quarter analysis of 5 years shows Aptevo Therapeutics' EBT stood at -$12.6 million in 2018, then grew by 23.82% to -$9.6 million in 2019, then increased by 28.75% to -$6.8 million in 2020, then skyrocketed by 40.75% to -$4.0 million in 2021, then crashed by 90.2% to -$7.7 million in 2022.
- Its last three reported values are -$7.7 million in Q4 2022, -$7.8 million for Q3 2022, and -$7.6 million during Q2 2022.